Andreas Argyrides
Stock Analyst at Oppenheimer
(4.39)
# 335
Out of 4,876 analysts
111
Total ratings
47.92%
Success rate
21.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALA KALA BIO | Assumes: Outperform | $15 | $5.26 | +185.44% | 1 | Jun 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Assumes: Outperform | $61 | $31.86 | +91.46% | 1 | Jun 2, 2025 | |
| AQST Aquestive Therapeutics | Assumes: Outperform | $15 → $7 | $3.25 | +115.38% | 5 | Jun 2, 2025 | |
| ABEO Abeona Therapeutics | Assumes: Outperform | $19 | $5.90 | +222.03% | 1 | Jun 2, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $60 → $34 | $10.05 | +238.31% | 1 | Jun 2, 2025 | |
| IFRX InflaRx | Maintains: Outperform | $6 → $3 | $0.83 | +260.32% | 2 | May 29, 2025 | |
| LQDA Liquidia | Downgrades: Underperform | $13 | $12.83 | +1.33% | 7 | May 19, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Outperform | $14 → $4 | $0.52 | +673.69% | 5 | May 16, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $155 → $90 | $12.34 | +629.34% | 1 | May 13, 2025 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | $15 → $9 | $2.16 | +316.67% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $47 → $15 | $13.51 | +11.03% | 8 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $173.17 | +4.52% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $12.35 | +183.40% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $3.08 | +744.16% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $8.16 | -14.22% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $47.29 | +119.92% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.81 | +516.52% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.30 | +592.31% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $18.08 | +5.09% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $19.48 | +48.87% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $8.75 | +140.00% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $17.23 | +1,200.06% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $23.60 | +141.53% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.79 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.71 | +885.36% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.77 | +165.25% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.56 | +1,694.37% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $54.10 | +29.39% | 6 | Aug 1, 2023 |
KALA BIO
Jun 2, 2025
Assumes: Outperform
Price Target: $15
Current: $5.26
Upside: +185.44%
Harmony Biosciences Holdings
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $31.86
Upside: +91.46%
Aquestive Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $3.25
Upside: +115.38%
Abeona Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $19
Current: $5.90
Upside: +222.03%
Dyne Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $60 → $34
Current: $10.05
Upside: +238.31%
InflaRx
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $0.83
Upside: +260.32%
Liquidia
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $12.83
Upside: +1.33%
Rani Therapeutics Holdings
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.52
Upside: +673.69%
Korro Bio
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $12.34
Upside: +629.34%
ProQR Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.16
Upside: +316.67%
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $13.51
Upside: +11.03%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $173.17
Upside: +4.52%
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $12.35
Upside: +183.40%
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $3.08
Upside: +744.16%
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $8.16
Upside: -14.22%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $47.29
Upside: +119.92%
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.81
Upside: +516.52%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.30
Upside: +592.31%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $18.08
Upside: +5.09%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $19.48
Upside: +48.87%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $8.75
Upside: +140.00%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $17.23
Upside: +1,200.06%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $23.60
Upside: +141.53%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.79
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.71
Upside: +885.36%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $3.77
Upside: +165.25%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.56
Upside: +1,694.37%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $54.10
Upside: +29.39%